

We claim:

1. A method of identifying an agent useful in treating Crohn's disease, comprising:

- 5 (a) culturing *P. fluorescens* under conditions that support growth;
- (b) contacting said *P. fluorescens* with an agent; and
- (c) assaying for reduced growth or viability of said *P. fluorescens* as compared to the growth or
- 10 viability in the absence of said agent, wherein said reduced growth or viability of said *P. fluorescens* indicates that said agent is an anti-*P. fluorescens* agent useful in treating Crohn's disease.

- 15 2. The method of claim 1, wherein said agent is an antibiotic.

3. A method of preventing or treating Crohn's disease in an individual, comprising administering to said individual an effective amount of an anti-*P. fluorescens*
- 20 agent identified according to the method of claim 1.

4. The method of claim 3, wherein said anti-*P. fluorescens* agent comprises one or more antibiotics.

5. A method of preventing or treating Crohn's disease in an individual, comprising administering to said
- 25 individual an effective amount of an anti-*Pseudomonas* agent.

0997641-101

14. The method of claim 13, wherein said *Pseudomonas* vaccine comprises killed whole *P. fluorescens*.

15. A method of preventing or treating Crohn's disease in an individual, comprising administering to said individual an effective dose of a purified *Pseudomonas* antigen, or a tolerogenic fragment thereof.

5 16. The method of claim 15, wherein said antigen is a *P. fluorescens* antigen.

17. The method of claim 16, wherein said antigen is pbrA, or a tolerogenic fragment thereof.

10 18. The method of claim 17, wherein pbrA has an amino acid sequence selected from the group consisting of SEQ ID NO: 2 or a tolerogenic fragment thereof and SEQ ID NO: 3 or a tolerogenic fragment thereof.

15 19. The method of claim 16, wherein said antigen is PFTR, or a tolerogenic fragment thereof, provided that the antigen is not I-2 or a fragment thereof.

20 20. The method of claim 19, wherein PFTR has the amino acid sequence SEQ ID NO: 5, or a tolerogenic fragment thereof.

20 21. The method of claim 15, wherein said *Pseudomonas* antigen is selected from the group consisting of an outer membrane protein, toxin, lipopolysaccharide (LPS), exotoxin A, TonB and a immunogenic fragment thereof.

09976451-101201
102107-15492660

5 *fluorescens* in said individual.

reduces the expression of pbrA.

a pbrA antisense nucleic acid molecule.

10 25. The method of claim 23, wherein said agent is
a sequence-specific ribonuclease.

15 or PFTR, thereby reducing the growth or viability of
P. fluorescens in said individual.

reduces the expression of PFTR.

20 a PFTR antisense nucleic acid molecule.

a sequence-specific ribonuclease.

an inhibitor of PFTR enzymatic function.

31. A method of diagnosing Crohn's disease in a individual, comprising:

- (a) obtaining a sample from said individual;
- 5 (b) contacting said sample with pbrA, or an immunoreactive fragment thereof, under conditions suitable to form a complex of pbrA, or said immunoreactive fragment thereof, and antibody to pbrA; and
- 10 (c) detecting the presence or absence of said complex,

wherein the presence of said complex indicates that said individual has Crohn's disease.

32. The method of claim 31, wherein the presence or absence of said complex is detected with a detectable
15 secondary antibody.

33. The method of claim 31, wherein said pbrA has an amino acid sequence selected from the group consisting of SEQ ID NO: 2 or an immunoreactive fragment thereof and SEQ ID NO: 3 or an immunoreactive fragment thereof.

102107-1549250

34. A method of diagnosing Crohn's disease in a individual, comprising:

- (a) obtaining a sample from said individual;
- (b) contacting said sample with PFTR, or an immunoreactive fragment thereof, under conditions suitable to form a complex of PFTR, or said immunoreactive fragment thereof, and antibody to PFTR; and
- (c) detecting the presence or absence of said complex,

provided that said immunoreactive fragment is not I-2 or a fragment thereof, and

wherein the presence of said complex indicates that said individual has Crohn's disease.

35. The method of claim 34, wherein the presence or absence of said complex is detected with a detectable secondary antibody.

36. The method of claim 34, wherein said PFTR has the amino acid sequence SEQ ID NO: 5, or an immunoreactive fragment thereof.